MedTrace Logo

Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration

NCT00539734 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-04-15

Study results available
· View outcomes & findings →

Summary

Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

ranibizumab

A single dose of 0.5 mg ranibizumab injected intravitreally.

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Patama Bhurayanontachai, MD · Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-12-31
Completion
2009-02-28

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539734 on ClinicalTrials.gov